Search Results
Claim Rejection and Denials for Providers on the Preclusion List to begin on April 1, 2019
Fact sheet
CMS Updates Drug Dashboards with Prescription Drug Pricing and Spending Data
This Administration’s version of the drug dashboards adds information on the manufacturers that are responsible for price increases and includes pricing and spending data for thousands more drugs across Medicare Parts B and D and Medicaid.
Press releaseOpioid Prescribing Mapping Tool Improved with Medicaid and Rural Data
New features offer local communities greater transparency into opioid prescribing rates.
Press releaseContract Year (CY) 2020 Medicare Advantage and Part D Drug Pricing Proposed Rule (CMS-4180-P)
CMS is committed to implementing President Trump’s blueprint to lower drug costs and reduce out-of-pocket costs for patients. In line with the policies discussed in the President’s blueprint, CMS issued a proposed rule on November 26, 2018 that solicits public comments on potential policies that would remove administrative hurdles to offer lower cost options to seniors and provide support for private sector partners by providing them the tools to lower the cost of prescription drugs.
Fact sheetCMS Takes Action to Lower Prescription Drug Costs by Modernizing Medicare
Today, the Centers for Medicare & Medicaid Services (CMS) proposed polices for 2020 to strengthen and modernize the Medicare Part C and D programs. The proposal would ensure that Medicare Advantage and Part D plans have more tools to negotiate lower drug prices, and the agency is also considering a policy that would require pharmacy rebates to be passed on to seniors to lower their drug costs at the pharmacy counter.
Press releaseRemarks by Administrator Seema Verma at the Biopharma Congress
Administrator Seema Verma's remarks regarding CMS’ drug pricing efforts given at the Biopharma Congress (As prepared for delivery – November 14, 2018)
Press releaseANPRM International Pricing Index Model for Medicare Part B Drugs
The Centers for Medicare & Medicaid Services (CMS) is committed to implementing President Trump’s blueprint to lower drug costs and reduce out-of-pocket costs for patients. In line with the policies discussed in the President’s blueprint, the CMS is soliciting public comments on potential options we may consider for testing changes to payment for certain separately payable Part B drugs and biologicals (“drugs”).
Fact sheetCMS Administrator Seema Verma Statement on Drug Industry Price Transparency Announcement
Press release
CMS Proposes to Require Manufacturers to Disclose Drug Prices in Television Ads
Proposed rule would further the Trump Administration’s commitment to lower prescription drug prices by requiring companies to list prices for prescription drugs covered in Medicare or Medicaid.
Press release